Pyridoxamine dihydrochloride

Pyridoxamine dihydrochloride is the dihydrochloride salt of pyridoxamine, one of the three natural vitamers of vitamin B6 alongside pyridoxine (the alcohol form) and pyridoxal (the aldehyde form). First isolated and characterized by Esmond Snell in 1944 during microbiological growth assay studies of the vitamin B6 group, pyridoxamine is distinguished from the other B6 vitamers by the presence of a 4-aminomethyl substituent on the pyridine ring, a structural feature that confers unique pharmacological properties not shared by pyridoxine or pyridoxal. Specifically, the combination of the 3-hydroxyl group and the 4-aminomethyl group endows pyridoxamine with a triple mechanism of action against the formation of advanced glycation end-products (AGEs) and advanced lipoxidation end-products (ALEs): (i) chelation of catalytic redox metal ions (Cu2+ and Fe3+) that drive oxidative degradation of the Amadori intermediate in the Maillard reaction; (ii) direct scavenging of toxic reactive carbonyl species generated during glucose and lipid degradation, including glyoxal, methylglyoxal, and glycolaldehyde; and (iii) trapping of reactive oxygen species through hydrogen-atom transfer and radical-adduct formation mechanisms. This triple mechanism was first characterized by Khalifah, Baynes, and Thorpe, who designated pyridoxamine as the founding member of the "Amadorin" class of post-Amadori AGE inhibitors, mechanistically distinct from aminoguanidine and other first-generation dicarbonyl scavengers.

The pharmacological interest in pyridoxamine for diabetic complications originated from preclinical demonstrations in streptozotocin-diabetic rats and Zucker obese rats, where the compound inhibited the development of nephropathy, retinopathy, neuropathy, and dyslipidemia with efficacy comparable or superior to aminoguanidine and without the toxicity concerns associated with nitric oxide synthase inhibition. BioStratum filed an Investigational New Drug application with the United States Food and Drug Administration in 1999, and two Phase 2 randomized, double-blind, placebo-controlled trials in 212 patients with type 1 and type 2 diabetes and overt nephropathy demonstrated that pyridoxamine significantly reduced the change from baseline in serum creatinine (p < 0.03), with particular efficacy in type 2 diabetic patients with elevated baseline serum creatinine (p = 0.007). NephroGenex subsequently acquired the program, obtained FDA Fast Track designation and Special Protocol Assessment for a Phase 3 PIONEER program under Subpart H accelerated approval, but paused development in 2016 owing to capital constraints and filed for Chapter 11 bankruptcy. The IND applications were withdrawn in 2017. In a separate development, a 2024 randomized controlled trial in 55 postmenopausal women with type 2 diabetes reported that pyridoxamine at 200 mg in the published literature for 12 months significantly increased femoral neck bone mineral density (p = 0.007) and reduced glycated hemoglobin (p = 0.04), extending the therapeutic rationale beyond nephroprotection to skeletal quality in diabetes.

The regulatory history of pyridoxamine is notable for the FDA ruling of January 2009 that excluded pyridoxamine from the definition of dietary supplements on the basis that the compound was under active investigation as a new drug, a decision that generated substantial controversy and subsequent citizen petitions. The compound remains available as a research-grade preparation. This monograph reviews the chemistry, synthesis, and structural class of pyridoxamine dihydrochloride; the triple mechanism of AGE and ALE inhibition; the pharmacokinetics of the B6 vitamer system; the preclinical pharmacology across multiple diabetic complication models; the clinical evidence base in diabetic nephropathy and bone quality; sourcing and quality verification; reconstitution and handling; stack interactions; adverse events; and a comparative assessment of five AGE-targeting compounds (aminoguanidine, alagebrium, benfotiamine, LR-90, and OPB-9195) against pyridoxamine on five competency standards.